

## Edarbi. - (40, 80 mg; Tablet, Oral)

<b>Generic Name</b>	Azilsartan Kamedoxomil	<b>Innovator</b>	Azurity (Arbor)
<b>Dosage</b>	40, 80 mg; Tablet, Oral	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Edarbi (azilsartan) is an angiotensin II receptor blocker (sometimes called an ARB). Azilsartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. Edarbi is used to treat high blood pressure (hypertension).		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.